Leiomyosarcoma of the vagina: case report and literature review

Leiomyosarcoma of the vagina is quite rare. Extensive search of the literature discloses 137 case reports published over the past 40 years. Collectively, these reports give only cursory guidelines for diagnosis, management, and prognosis. We add another case to the sparse literature on leiomyosarcoma of the vagina. Treatment consisted of surgical excision. Tumor was found to extend to the margin of the excised specimen. The malignancy quickly recurred with lung metastases and the patient died. The very poor prognosis associated with this lesion emphasizes the critical need for early diagnosis and expeditious therapy. In the interest of improving salvage by prompt recognition and intervention, it is important for health-care professionals to be knowledgeable about and alert to this condition.     

Identification of genes associated with ovarian cancer metastasis using microarray expression analysis

Although the transition from early- to advanced-stage ovarian cancer is a critical determinant of survival, little is known about the molecular underpinnings of ovarian metastasis. We hypothesize that microarray analysis of global gene expression patterns in primary ovarian cancer and metastatic omental implants can identify genes that underlie the metastatic process in epithelial ovarian cancer. We utilized Affymetrix U95Av2 microarrays to characterize the molecular alterations that underlie omental metastasis from 47 epithelial ovarian cancer samples collected from multiple sites in 20 patients undergoing primary surgical cytoreduction for advanced-stage (IIIC/IV) serous ovarian cancer. Fifty-six genes demonstrated differential expression between ovarian and omental samples (P < 0.01), and twenty of these 56 differentially expressed genes have previously been implicated in metastasis, cell motility, or cytoskeletal function. Ten of the 56 genes are involved in p53 gene pathways. A Bayesian statistical tree analysis was used to identify a 27-gene expression pattern that could accurately predict the site of tumor (ovary versus omentum). This predictive model was evaluated using an external data set. Nine of the 27 predictive genes have previously been shown to be involved in oncogenesis and/or metastasis, and 10/27 genes have been implicated in p53 pathways. Microarray findings were validated by real-time quantitative PCR. We conclude that gene expression patterns that distinguish omental metastasis from primary epithelial ovarian cancer can be identified and that many of the genes have functions that are biologically consistent with a role in oncogenesis, metastasis, and p53 gene networks.     

Lähmung des N. hypoglossus nach operativem Eingriff – Behandlung mit Akupunktur

Acupuncture is able to accelerate the process of healing significantly when employed in cases of nerve paresis as shown in the following analysis. The patient's constant condition of speech and swallowing impediment before treatment changed relatively fast after starting acupuncture treatment. It is self evident that we took into account the primary disease (AIDS) and its problems. The simplicity of a complementary treatment with acupuncture according to the possible results should make us consider the use of acupuncture as an important way to treat paresis in the early subacute phase and if possible during clinical stay.     

紫杉醇联合希罗达治疗晚期胃癌的初步观察

目的 观察联合希岁达与紫杉醇治疗晚期胃癌的疗效与毒副反应。方法 对68例晚期胃癌患者进行回顾性统计分析。结果 CR6％，PR47％，NC22％，PD25％。症状缓解率81％。一年总生存率72％。平均缓解时间5．5月。化疗副反应包括恶心呕吐（86％），手足综合征（45％）；Ⅰ、Ⅱ度骨髓抑制（55％）及Ⅲ、Ⅳ度骨髓抑制（12％）；无化疗相关死亡。结论 希罗达加紫杉醇方案对晚期胃癌疗效较好，毒副作用较轻。     

阿米福汀对同步放化疗杀伤肺癌细胞作用的影响

目的　探讨阿米福汀在多烯紫杉醇和同步放射治疗非小细胞肺癌过程中对肺癌组织细胞是否有保护作用。方法　使用MTT方法评价在多烯紫杉醇和同步照射 (10Gy)体外培养的SPC A1肺癌细胞过程中 ,阿米福汀对SPC A1肺癌细胞的影响 ;以Lewis肺癌荷瘤鼠模型评价在多烯紫杉醇同步放射 (10Gy)在体Lewis肺癌过程中 ,阿米福汀对Lewis肺癌的影响。结果　体外实验表明同步放化疗加阿米福汀组和同步放化疗组的吸光度分别相当于对照组的 2 2 .8%和 2 4 .4 % ,两组之间比较 ,经过t检验P >0 .0 5。体内实验表明 ,同步放化疗加阿米福汀组和同步放化疗组在实验观察的 2 0d内 ,相同时间点两组动物的肿瘤体积差异无统计学意义。结论　在多烯紫杉醇和放疗同步治疗肺癌过程中 ,阿米福汀无论是对离体还是在体的肿瘤细胞没有保护作用 ,多烯紫杉醇和同步放射治疗肺癌的疗效不会因为使用阿米福汀而减弱     

Combined androgen blockade in the management of advanced prostate cancer: A sensible or ostensible approach

BACKGROUND: To compare the efficacy of orchiectomy alone and orchiectomy plus flutamide in treating patients with advanced carcinoma prostate. MATERIALS AND METHODS: The study was initiated on 1 July 1997 and closed after enrolling 100 patients on 30 June 2000. Patients were prospectively randomized to orchiectomy alone (O) and orchiectomy plus flutamide (OF). A complete response (CR) was defined as the normalization of bone scans and serum prostate-specific antigen (PSA) levels returning to normal (< 4 ng/mL). A partial response (PR) was defined as a 50% reduction in metastasis mass compared to the initial study or a decrease in the PSA level of 50% of the initial value. Progressive disease (PD) was defined as the development of any new hot spot on bone scan or any increase in previously existing PSA level by 25%. RESULTS: A total of 100 patients were entered in the study. The maximum percentage change in PSA levels in both groups was found in the first 3 months after orchiectomy, that is, 95% and 97% for the O and OF groups, respectively. In more than 80% of the patients this decrease in PSA was maintained for 3 years. The mean percentage change at 3 years in the O and OF groups was 70% and 75% (P = 0.95), respectively, and the overall response rate (CR + PR) was 88.50% and 86.53% in the two groups, respectively (P = 0.85). The follow-up period ranged between 3 and 5 years (mean, 3.5 years). The mean time to progression was 27 and 29 months in the O and OF groups, respectively. The overall survival rate at 3 and 5 years in two treatment groups was 45.83% and 48.07%, 20.83% and 23.07% in the O and OF groups, respectively (P = 0.75). CONCLUSIONS: Maximum percentage decrease in PSA is seen within the first 3 months of therapy. Orchiectomy alone is as effective as combination therapy in decreasing serum PSA. Overall survival at 3 and 5 years in the orchiectomy only group was as good as that of combination therapy. These data suggest that the routine addition of flutamide to orchiectomy is not advisable.     

食管癌与贲门癌术后胃排空障碍15例临床分析

目的：探讨食管癌、贲门癌术后胃排空障碍的病因、诊断及防治。方法：回顾性分析15例食管癌、贲门癌术后胃排空障碍的病因，区分功能性及机械性胃排空障碍的诊断，提出防治措施。结果：15例患者中11例功能性胃排空障碍，经保守治疗治愈。4例机械性胃排空障碍经手术治愈。常规行幽门成形术者，无胃排空障碍发生。结论：食管癌、贲门癌术后胃排空障碍的发生与手术方式、术中操作及迷走神经干的切断等因素有关。应规范手术操作，常规行幽门成形术及辅以胃肠动力药物等进行治疗。     

生三七对肝纤维化小鼠血液流变学的影响

目的:观察生三七对肝纤维化小鼠血液流变学的影响。方法:复制小鼠中毒性肝纤维化模型,生三七粉灌胃6周,检测全血粘度、血浆粘度、红细胞压积等血液流变学参数,并行肝脏病理组织切片检测。结果:与空白对照组比较,肝纤维化模型组小鼠全血粘度、血浆粘度、红细胞压积明显增高(P<0.05,P<0.01),生三七治疗后小鼠全血粘度、血浆粘度、红细胞压积明显降低(P<0.05,P<0.01);肝脏病理组织切片显示使用生三七后,肝纤维化程度有明显改善。结论:生三七可降低血液粘度,延缓肝纤维化的发展。